Clinical Trials Logo

Filter by:
NCT ID: NCT06276010 Not yet recruiting - Clinical trials for Extracorporeal Membrane Oxygenation Complication

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.

NCT ID: NCT06275555 Not yet recruiting - Clinical trials for Extracorporeal Membrane Oxygenation Complication

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

NCT ID: NCT06272747 Not yet recruiting - Healthy Adults Clinical Trials

A Phase I Study of XH-S003 in Healthy Volunteers

Start date: February 22, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.

NCT ID: NCT06272565 Not yet recruiting - Clinical trials for Diabetic Retinopathy

Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage

DR
Start date: March 1, 2024
Phase:
Study type: Observational

Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients. This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents, and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage. DR patients with macular edema will receive anti-vascular endothelial growth factor (anti-VEGF) treatment; these patients will be divided into two groups: responders group and non-responders group.

NCT ID: NCT06269211 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression

TOPLINE
Start date: March 30, 2024
Phase: Phase 2
Study type: Interventional

The study is a prospective, open label, multicenter, single arm Phase II clinical trial, aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC patients with EGFR mutations and PD-L1 positive expression, providing a novel perspective for further improving the prognosis of NSCLC patients. This study will provide valuable information for further clinical trials of neoadjuvant Toripalimab and other immune checkpoint inhibitors in NSCLC patients with EGFR mutations and PD-L1 positive expression.

NCT ID: NCT06267612 Not yet recruiting - Heart Failure Clinical Trials

Corheart 6 LVAS Long-term Follow-up Study

Start date: February 10, 2024
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to explore the long-term efficacy and safety of the Corheart 6 Left Ventricular Assist System (LVAS) as a treatment for patients with advanced heart failure. The study will be a single-arm, prospective, single-center, non-blinded, and non-randomized study with a follow-up duration of five years.

NCT ID: NCT06266910 Not yet recruiting - Myopia Clinical Trials

Effects of Autostereoscopic 3D Visual Training on Binocular Vision Function of Myopes

Start date: February 15, 2024
Phase: N/A
Study type: Interventional

This study intends to conduct a relatively comprehensive binocular visual function examination and follow-up on two groups of myopic subjects, one receiving autostereoscopic 3D vision training and the other receiving 2D vision training as a control. The aim is to explore the impact of autostereoscopic 3D vision training on the accommodation and convergence functions of myopes. Additionally, synchronized EEG-fNIRS signals will be collected to investigate whether changes in binocular visual function are accompanied by corresponding alterations in brain function.

NCT ID: NCT06265545 Not yet recruiting - AML Clinical Trials

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

NCT ID: NCT06263205 Not yet recruiting - Pain, Postoperative Clinical Trials

Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques

Dressing
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess the effectiveness and safety of non-dressing (exposed wound) versus dressing techniques in postoperative wound management for patients with gastrointestinal tumors. The main questions it aims to answer are: 1. Does non-dressing of postoperative wounds in gastrointestinal tumor surgery provide equivalent or better wound healing compared to traditional dressing techniques? 2. Can non-dressing of postoperative wounds reduce patient pain and healthcare costs? Participants in this study, who are diagnosed with gastrointestinal tumors and undergoing surgery, will be randomly assigned to either the non-dressing group or the dressing group. The non-dressing group will have their surgical wounds left exposed after initial postoperative care, while the dressing group will receive regular wound dressing changes every 48-72 hours. Researchers will compare these two groups to see if there are differences in the rate of wound complications, pain levels, and overall healthcare costs. This study aims to provide evidence-based recommendations for postoperative wound care in gastrointestinal tumor surgeries, potentially improving patient outcomes and reducing medical expenses.

NCT ID: NCT06261359 Not yet recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma (PDAC)

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

Start date: February 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.